SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development
On October 2, 2024, two travelers in Hamburg, Germany were hospitalized due to displaying symptoms consistent with Marburg virus. The two...
264 Views
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update. The company...
133 Views
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update. The company...
148 Views
SNGX: Positive Interim Results for HyBryte in Investigator-Initiated Study in CTCL Raising Valuation to 35
On July 9, 2024, Soligenix, Inc. (SNGX) announced positive interim results for HyBryte in an open-label, investigator-initiated study in patients...
189 Views
SNGX: Valuation Change Based on Reverse Split
On June 6, 2024, Soligenix, Inc. (SNGX) enacted a reverse stock split at a ratio of 1 post-split share for every 16 pre-split shares. Our...
142 Views